Adherence to treatment in adults with cystic fibrosis

Conditions

Specialty: Respiratory disorders, Primary sub-specialty: Respiratory disorders

Martin J Wildman, Alicia O’Cathain, Daniel Hind, Chin Maguire, Madelynne A Arden et al. (28 authors)

Programme Grants for Applied Research2021-10-0111 citations

10.3310/pgfar09110

Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation

Daniel Hind, Sarah J Drabble, Madelynne A Arden, Laura Mandefield, Simon Waterhouse et al. (21 authors)

BMJ Open2020-10-0116 citations

10.1136/bmjopen-2020-039089

Mechanisms of Action of a Web-Based Intervention With Health Professional Support to Increase Adherence to Nebulizer Treatments in Adults With Cystic Fibrosis: Qualitative Interview Study

Sarah J Drabble, Alicia O’Cathain, Alexander J. Scott, Madelynne A Arden, Samuel Keating et al. (8 authors)

Journal of Medical Internet Research2020-07-2223 citations

10.2196/16782

Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study

Daniel Hind, Sarah J Drabble, Madelynne A Arden, Laura Mandefield, Simon Waterhouse et al. (21 authors)

BMC Pulmonary Medicine2019-04-1139 citations

10.1186/s12890-019-0834-6

Role of habit in treatment adherence among adults with cystic fibrosis

Zhe Hui Hoo, Benjamin Gardner, Madelynne A Arden, Simon Waterhouse, Stephen J. Walters et al. (10 authors)

Thorax2018-06-0937 citations

10.1136/thoraxjnl-2017-211453

Interventions

Study participants will be randomised to either the intervention arm (CFHealthHub) or control arm (usual care). Participants in both groups will contribute adherence data to CFHealthHub but only those

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with CF and within CF registry 2. Aged 16 years and above 3. Taking inhaled mucolytics or antibiotics via a chipped nebuliser (e.g. eTrack or I-Neb or able and willing to take via eTrack or I-Neb)

Exclusion criteria

Exclusion criteria: 1. Post-lung transplant 2. People on the active lung transplant list 3. Patients receiving palliative care, with palliative intent, for whom trial participation could be a burden 4. Participants who lack capacity to give informed consent 5) Participants using dry powder devices to take antibiotics or mucolytics

Design outcomes

Primary

Measure	Time frame
Number of pulmonary exacerbations of cystic fibrosis is measured using the modified Fuchs Criteria at baseline and 5 (+/- 1) months	—

Secondary

Measure	Time frame
1. Generic health status is measured using the EQ5D5L at baseline and 5 (+/- 1) months 2. Assessment of patient knowledge, skill, and confidence for self-management is measured using the Patient Activation Measure -13 at baseline and 5 (+/- 1) months 3. Life chaos is measured using the Confusion, Hubbub And Order Scale -6 at baseline and at 5 +/- 1 months 4. Habit-based behaviour patterns are measured using the Self-Reported Behavioural Automaticity Index at baseline and 5 (+/- 1) months 5. Disease specific health-related quality of life is measured using the Cystic Fibrosis Questionnaire-Revised at baseline and 5 (+/- 1) months 6. Depressive disorder severity is measured using the Patient Health Questionnaire depression scale -8 at baseline and 5 (+/- 1) months 7. Medication adherence is measured using the Medication Adherence Data -3 at baseline and 5 (+/- 1) months 8. Anxiety severity is measured using the General Anxiety Disorder -7 at baseline and 5 (+/- 1) months 9. Perceived necessities and concerns for nebuliser treatment are measured using the Capability Opportunity Motivation–Beliefs about Medicines Questionnaire at baseline and 5 (+/- 1) months 10. Resource use data is collected using the resource use form developed for the study at 5 (+/- 1) months 11. Acceptability of the intervention is determined through qualitative interviews with patients and members of the multidisciplinary CF team at 5 (+/- 1) months 12. Condition severity is measured using FEV1/FVC at routine clinic visits from baseline to study end	—

Measure

Time frame

1. Generic health status is measured using the EQ5D5L at baseline and 5 (+/- 1) months 2. Assessment of patient knowledge, skill, and confidence for self-management is measured using the Patient Activation Measure -13 at baseline and 5 (+/- 1) months 3. Life chaos is measured using the Confusion, Hubbub And Order Scale -6 at baseline and at 5 +/- 1 months 4. Habit-based behaviour patterns are measured using the Self-Reported Behavioural Automaticity Index at baseline and 5 (+/- 1) months 5. Disease specific health-related quality of life is measured using the Cystic Fibrosis Questionnaire-Revised at baseline and 5 (+/- 1) months 6. Depressive disorder severity is measured using the Patient Health Questionnaire depression scale -8 at baseline and 5 (+/- 1) months 7. Medication adherence is measured using the Medication Adherence Data -3 at baseline and 5 (+/- 1) months 8. Anxiety severity is measured using the General Anxiety Disorder -7 at baseline and 5 (+/- 1) months 9. Perceived necessities and concerns for nebuliser treatment are measured using the Capability Opportunity Motivation–Beliefs about Medicines Questionnaire at baseline and 5 (+/- 1) months 10. Resource use data is collected using the resource use form developed for the study at 5 (+/- 1) months 11. Acceptability of the intervention is determined through qualitative interviews with patients and members of the multidisciplinary CF team at 5 (+/- 1) months 12. Condition severity is measured using FEV1/FVC at routine clinic visits from baseline to study end

—

Countries

England, United Kingdom

Contacts

Public ContactChin Maguire

c.maguire@sheffield.ac.uk+44 114 222 0717

Outcome results

None listed